menu
    • menu
    [{"orgOrder":0,"company":"Overland Pharmaceuticals","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Overland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland Pharmaceuticals \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Overland Pharmaceuticals \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"Overland Pharmaceuticals","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Overland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland Pharmaceuticals \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Overland Pharmaceuticals \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"Overland Pharmaceuticals","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Overland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland Pharmaceuticals \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Overland Pharmaceuticals \/ Overland Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Overland Pharmaceuticals

    Menu

    Overland Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loncastuximab Tesirine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : ADC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZY...

                            Details : Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is approved by FDA and EU for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

                            Product Name : Zynlonta

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 24, 2023

                            Lead Product(s) : Loncastuximab Tesirine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : ADC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loncastuximab Tesirine,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : ADC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab i...

                            Details : ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

                            Product Name : Zynlonta

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 11, 2022

                            Lead Product(s) : Loncastuximab Tesirine,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : ADC Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Overland Pharmaceuticals

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loncastuximab Tesirine,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Overland ADCT BioPharma

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

                            Details : ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT BioPharma. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics, 49%.

                            Product Name : Lonca

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            December 14, 2020

                            Lead Product(s) : Loncastuximab Tesirine,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Overland ADCT BioPharma

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth